Verrica Pharmaceuticals (VRCA) Stock Overview
A dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
VRCA Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Verrica Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.60 |
| 52 Week High | US$24.40 |
| 52 Week Low | US$3.82 |
| Beta | 1.92 |
| 1 Month Change | -0.80% |
| 3 Month Change | 5.35% |
| 1 Year Change | -76.19% |
| 3 Year Change | -85.80% |
| 5 Year Change | -93.34% |
| Change since IPO | -96.80% |
Recent News & Updates
Recent updates
Turnaround Plan Will Commercialize YCANTH And Advance Pipeline
Cost reductions and focus on YCANTH commercialization could improve future revenues and net margins, aiding the turnaround plan.The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%
Oct 03
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 17With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For
Aug 16Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jul 21Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?
Jan 11Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation
Jun 28We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely
Feb 05Vectoring Back In On Verrica Pharmaceuticals
Aug 31Verrica Pharmaceuticals reports insider buying
Jul 06Verrica Pharmaceuticals stock slides on proposed share offering
Jun 29Shareholder Returns
| VRCA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.6% | 1.6% | 0.5% |
| 1Y | -76.2% | -13.9% | 15.7% |
Return vs Industry: VRCA underperformed the US Pharmaceuticals industry which returned -13.9% over the past year.
Return vs Market: VRCA underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| VRCA volatility | |
|---|---|
| VRCA Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VRCA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRCA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 71 | Jayson Rieger | www.verrica.com |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts.
Verrica Pharmaceuticals Inc. Fundamentals Summary
| VRCA fundamental statistics | |
|---|---|
| Market cap | US$52.85m |
| Earnings (TTM) | -US$48.60m |
| Revenue (TTM) | US$14.70m |
Is VRCA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRCA income statement (TTM) | |
|---|---|
| Revenue | US$14.70m |
| Cost of Revenue | US$9.69m |
| Gross Profit | US$5.01m |
| Other Expenses | US$53.61m |
| Earnings | -US$48.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.15 |
| Gross Margin | 34.07% |
| Net Profit Margin | -330.52% |
| Debt/Equity Ratio | -213.1% |
How did VRCA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 13:15 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Verrica Pharmaceuticals Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Oren Livnat | H.C. Wainwright & Co. |